Bayer's Finerenone Marches Ahead; Is Phase III A Hill Too Steep?
This article was originally published in Scrip
Executive Summary
Bayer AG's Phase III program for its heart failure drug finerenone could create a dual indication product with a strong label, but those potential rewards carry their own risks, since it is uncertain if the design can adequately address appropriate dosing, the crucial hyperkalemia safety factor, and accommodation of Novartis AG's just-approved Entresto (sacubitril/valsartan).